DTwP-HepB-Hib vaccine - Crucell/Novartis Vaccines

Drug Profile

DTwP-HepB-Hib vaccine - Crucell/Novartis Vaccines

Alternative Names: DTP-HepB-Hib; DTwP-HepB-Hib; Fully liquid 5-in-1 pentavalent vaccine (Quinvaxem) - Crucell; Quinvaxem

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Berna Biotech; Novartis Vaccines
  • Developer Crucell; Novartis Vaccines
  • Class Haemophilus vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus

Most Recent Events

  • 01 Apr 2014 Crucell completes a phase III trial in Diphtheria, Pertussis, Tetanus, Hepatitis B and Haemophilus Infections (prevention, in infants) in the Philippines (NCT01917357)
  • 05 Aug 2013 Crucell plans a phase III trial for Diphtheria, Pertussis, Tetanus, Hepatitis B and Haemophilus Infections (prevention, in infants) in Philippines (NCT01917357)
  • 31 Dec 2011 Phase-III clinical trials in Diphtheria (prevention, in infants) in India (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top